ライフサイエンスコーパス: sleepiness

1 epiness) to 24 points (high level of daytime sleepiness).

2 0-24, with values <10 suggesting no daytime sleepiness).

3 ESS; range, 0-24; >10 indicates pathological sleepiness).

4 ated with the LPP even after controlling for sleepiness.

5 so associated with reduced AHI and excessive sleepiness.

6 on reward sensitivity either directly or via sleepiness.

7 healthy subjects, which are associated with sleepiness.

8 This effect was related to the level of sleepiness.

9 se (CAD), many of whom do not report daytime sleepiness.

10 Food consumption is thought to induce sleepiness.

11 he relationship between mild OSA and daytime sleepiness.

12 y, poor sleep quality, and excessive daytime sleepiness.

13 omycin on objective vigilance and subjective sleepiness.

14 ansient but substantial increases in daytime sleepiness.

15 delayed sleep habits, and excessive daytime sleepiness.

16 ures include snoring, witnessed apnoeas, and sleepiness.

17 study for patients with unexplained daytime sleepiness.

18 y significant sleep disturbances and daytime sleepiness.

19 is a common disease, responsible for daytime sleepiness.

20 excessive sleep, and its links to excessive sleepiness.

21 p deprivation-induced increase in subjective sleepiness.

22 ed evening socializing associated with lower sleepiness.

23 ociated with reduced alertness and increased sleepiness.

24 iness scale, 1312 (28.5%) reported excessive sleepiness.

25 y significant decrease in subjective daytime sleepiness.

26 thalamic injury, with inactivity and daytime sleepiness.

27 imilar in terms of their impact on objective sleepiness.

28 he recommended 8-10 h and 18% report daytime sleepiness.

29 Scale (ESS-IR) was used to assess of daytime sleepiness.

30 job discrimination also predicted new-onset sleepiness.

31 her dietary intervention may improve daytime sleepiness.

32 ng AHI), subjective sleepiness, or objective sleepiness.

33 for fluctuations in 1/f aperiodic signal and sleepiness.

34 he most common neurological cause of chronic sleepiness.

35 in AHI, subjective sleepiness, or objective sleepiness.

36 leep quality, insomnia symptoms, and daytime sleepiness.

37 ud snoring, nocturnal awakening, and daytime sleepiness.

38 /hypocretin (OH) neurons causes pathological sleepiness [1-4], whereas OH hyperactivity is associated

39 nterval): 2.97 (2.65-3.34)), regular daytime sleepiness (2.66 (2.34-3.01)), and regular insomnia (2.3

40 nd 1.33; P < 0.001 for all domains), daytime sleepiness (-2.92; P < 0.001), mood state (-4.24; P = 0.

41 h risk for OSAS, 46.3% had excessive daytime sleepiness, 41.5% were positive for both the Bq and ESS,

42 y trial showed no more chronic sleep loss or sleepiness across trial days among interns in flexible p

43 annoyance, disturbs sleep and causes daytime sleepiness, affects patient outcomes and staff performan

44 ions, moving violations, aggressive driving, sleepiness, alcohol abuse, metabolic disorders, and mult

45 Subjective sleepiness also decreased significantly with time awake

46 Acute melatonin suppression and subjective sleepiness also had a dose-dependent response to light e

47 ommon presenting symptom of OSA is excessive sleepiness, although this symptom is reported by as few

48 n insomnia, 82.7% of the variance in daytime sleepiness and 82.3% of the variance in anxiety [p < 0.0

49 imed to investigate the relationship between sleepiness and a behavior strongly associated with bette

50 Next-morning sleepiness and alertness were also assessed.

51 Sleep duration and morning sleepiness and alertness were compared between the two g

52 Next-morning sleepiness and alertness were not different between nigh

53 gth, oxygen desaturation, next-day perceived sleepiness and alertness.

54 verity, upper airway physiology and next-day sleepiness and alertness.

55 d by chronic, debilitating excessive daytime sleepiness and can be associated with cataplexy, sleep p

56 sleep, is characterized by excessive daytime sleepiness and cataplexy, a loss of muscle tone triggere

57 (NT1) is characterized by excessive daytime sleepiness and cataplexy, accompanied by sleep-wake symp

58 Narcolepsy is characterized by chronic sleepiness and cataplexy, episodes of profound muscle we

59 Narcolepsy is characterized by excessive sleepiness and cataplexy, sudden episodes of muscle weak

60 Narcolepsy is characterized by chronic sleepiness and cataplexy-sudden muscle paralysis trigger

61 olepsy, a condition characterized by chronic sleepiness and cataplexy.

62 disorder characterized by excessive daytime sleepiness and cataplexy.

63 which is characterized by excessive daytime sleepiness and cataplexy.

64 a significant increase in daytime subjective sleepiness and changes in the EEG architecture of a subs

65 as been implicated in pathways that generate sleepiness and cognitive impairments, but existing mathe

66 Sleepiness and distress, when modeled together, showed l

67 nificantly more likely to experience daytime sleepiness and dozing during daytime activities.

68 n, which is often characterized by excessive sleepiness and fatigue.

69 oor maintenance of wakefulness indicative of sleepiness and fragmented sleep and lacked any electroph

70 ocytes throughout the brain causes excessive sleepiness and fragmented wakefulness during the nocturn

71 were associated with poorer sleep, increased sleepiness and increased levels of fatigue.

72 etween increased levels of excessive daytime sleepiness and increased measures for adiposity traits (

73 older people with OSA syndrome, CPAP reduces sleepiness and is marginally more cost effective over 12

74 Because of the strong interactions between sleepiness and motivation, the role of sleepiness was al

75 The most common unrelated symptoms included sleepiness and neck pain.

76 Self-reported measures of sleepiness and objective measures of auditory performanc

77 nts receiving escitalopram had more frequent sleepiness and obstipation than did those in the other t

78 , respectively, narcolepsy excessive daytime sleepiness and poor sleep quality.

79 Narcolepsy with cataplexy, characterized by sleepiness and rapid onset into REM sleep, affects 1 in

80 ure are recommended for those with excessive sleepiness and resistant hypertension.

81 ver, racial/ethnic disparities in reports of sleepiness and sleep complaints are inconsistent.

82 to explore the relationship between daytime sleepiness and the risk of ischemic stroke and vascular

83 ermore, their increased levels of subjective sleepiness and their decreased sleep efficiency were sig

84 Daytime sleepiness and time to fall asleep decreased during weig

85 ted with increases in fatigue (tiredness and sleepiness) and with deterioration in cognitive performa

86 edical trainees, but their effects on sleep, sleepiness, and alertness are largely unknown.

87 ted sleep characteristics, excessive daytime sleepiness, and chronotype using the Pittsburgh Sleep Qu

88 s; polysomnography; and symptoms of fatigue, sleepiness, and depression.

89 lf-reported parental sleep duration, daytime sleepiness, and dozing among employed adults.

90 cating patients about the risks of excessive sleepiness, and encouraging clinicians to become familia

91 The degree of performance impairment, sleepiness, and homeostatic sleep-pressure response to s

92 ivid dreams, insomnia, nausea, constipation, sleepiness, and indigestion.

93 ant interactions between eczema and fatigue, sleepiness, and insomnia as predictors of poorer overall

94 ent-reported measures of depression, daytime sleepiness, and quality of life.

95 e, the visual analog scale score for daytime sleepiness, and sleep log-derived and actigraphy-derived

96 reased nocturnal activity, excessive daytime sleepiness, and weight loss.

97 he prevalence of insomnia, excessive daytime sleepiness, anxiety and depression among African gamers,

98 clinical features (i.e., significant daytime sleepiness, anxiety and depression symptoms, potential f

99 s containing validated measures on insomnia, sleepiness, anxiety, depression and gaming addiction.

100 There was no difference in daytime sleepiness, anxiety, depression, impulsive-compulsive di

101 igue (aOR, 1.59; 95% CI, 1.16-2.19), daytime sleepiness (aOR, 1.81; 95% CI, 1.28-2.55), or insomnia (

102 Sleepiness, as assessed by a visual analog scale, was si

103 .6]; 13 trials, 543 participants), excessive sleepiness assessed by ESS score (WMD, -2.0 [95% CI, -2.

104 ine/after AAC; (3) hourly ammonia/subjective sleepiness assessment for 8 hours after AAC; (4) sleep E

105 Self-reported daytime sleepiness associated with increased risk for all-cause

106 oving wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep

107 Secondary outcomes were subjective sleepiness at 12 months, plus objective sleepiness, qual

108 nea and hypopnea events and patient-reported sleepiness at 6 months.

109 ystem disorders, including excessive daytime sleepiness, attention deficit hyperactivity disorder, Al

110 turbances (general, perceived sleep quality, sleepiness, awakenings, and sleep efficiency), sleep dur

111 e associated with improvements in attention, sleepiness, behavior, and quality of life, and that chan

112 This study supports the notion that daytime sleepiness, but not nighttime sleeping duration, is one

113 Subjective sleepiness, but not psychomotor vigilance, improved duri

114 designing a drug that could treat excessive sleepiness by promoting alertness.

115 disorder characterized by excessive daytime sleepiness, cataplexy, hypnagonic hallucinations, sleep

116 criteria for diencephalic encephalitis with sleepiness, cataplexy, hypocretin deficiency, and centra

117 anxiety and depressive symptoms, and daytime sleepiness compared with conservative treatment.

118 Greater sleepiness correlated with higher burnout by means of lo

119 ing (rendering >292,000 activity and >70,000 sleepiness datapoints).

120 Subjects had few symptoms, that is, sleepiness, depression, anxiety, and cognitive deficits.

121 be accompanied by a persistence of excessive sleepiness despite adherence.

122 rial stiffness), neurobehavioral (subjective sleepiness, driving simulator performance), and quality

123 In contrast, sleepiness, driving simulator performance, and disease-s

124 ect of meditation on the LPP, such that less sleepiness during meditation, but not the control audio,

125 ng chronotypes reported a faster increase in sleepiness during the day than evening chronotypes, whic

126 Excessive daytime sleepiness (EDS) affects 10-20% of the population and is

127 xploring the links between excessive daytime sleepiness (EDS) and vulnerability to infectious disease

128 tment of disorders such as excessive daytime sleepiness (EDS) as well as other sleep or cognitive dis

129 fety and efficacy of LT on excessive daytime sleepiness (EDS) associated with PD.

130 We assessed whether excessive daytime sleepiness (EDS) at baseline was associated with subsequ

131 Excessive daytime sleepiness (EDS) can be caused by insufficient sleep but

132 Excessive daytime sleepiness (EDS) is common and disabling in Parkinson's

133 ake cycle characterized by excessive daytime sleepiness (EDS), cataplexy, nighttime sleep disturbance

134 g risk, inquiring about additional causes of sleepiness, educating patients about the risks of excess

135 urgh Sleep Quality Index [PSQI]) and daytime sleepiness (Epworth Sleepiness Scale [ESS]).

136 sleepiness, patients with excessive daytime sleepiness (Epworth Sleepiness Scale score >/=10) had a

137 Patients with self-reported daytime sleepiness (Epworth Sleepiness Scale score >10) and an a

138 pnea-hypopnea index >/=15/h) without daytime sleepiness (Epworth Sleepiness Scale score <10) were ran

139 ODI), apnea-hypopnea index (AHI), subjective sleepiness (Epworth Sleepiness Scale score), and objecti

140 (Pittsburgh Sleep Quality Index) and daytime sleepiness (Epworth Sleepiness Scale), and circadian mar

141 olepsy is characterized by excessive daytime sleepiness, fragmentation of nighttime sleep, and catapl

142 n/hypocretin signaling, resulting in chronic sleepiness, fragmented non-rapid eye movement sleep, and

143 Excessive daytime sleepiness has emerged as one of the most common, but of

144 rome occurs, which includes fever, anorexia, sleepiness, hyperalgesia and elevated corticosteroid sec

145 sleepier on the MSLT and reported increased sleepiness, hypnagogic hallucinations and cataplexy-like

146 Daytime sleepiness impairs cognitive ability, but recent evidenc

147 es sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.

148 dered the first-line treatment for excessive sleepiness in adult patients with narcolepsy.

149 ncrease in ammonia concentrations/subjective sleepiness in both patients and healthy volunteers; (ii)

150 Excessive daytime sleepiness in CD patients may be driven by factors beyon

151 morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.

152 ed (OR 3.24, 95% CI 1.73-6.06) and excessive sleepiness in connection with evening shifts decreased (

153 o the DASH-style diet and scores for daytime sleepiness in crude model (beta= -0.12; P=0.005).

154 bles associated with longitudinal changes in sleepiness in early PD.

155 e identify 42 loci for self-reported daytime sleepiness in GWAS of 452,071 individuals from the UK Bi

156 f a genetic risk score of 42 SNPs on daytime sleepiness in independent Scandinavian cohorts and on ot

157 nificantly increased wakefulness and reduced sleepiness in participants with obstructive sleep apnea

158 ting effects, for the treatment of excessive sleepiness in participants with obstructive sleep apnea

159 However, treatment of mild OSA may improve sleepiness in patients who are sleepy at baseline and im

160 moting effects, for the treatment of daytime sleepiness in patients with moderate to severe obstructi

161 atment of impaired wakefulness and excessive sleepiness in patients with narcolepsy.

162 on (SF) appear to underlie excessive daytime sleepiness in patients with sleep apnea (OSA).

163 Circadian dysfunction may underlie excessive sleepiness in PD.

164 le increases in subjective and physiological sleepiness in response to chronic sleep loss.

165 There was a significant reduction in sleepiness in the positive airway pressure therapy group

166 ion, insomnia symptoms and excessive daytime sleepiness in the UK Biobank (n = 112,586).

167 clarithromycin, have been reported to reduce sleepiness in these patients.

168 e pharmacologic options for the treatment of sleepiness in this population are limited.

169 developing an effective method for detecting sleepiness in vulnerable populations.

170 Sleepiness increased motivation to choose the high-effor

171 dical disorder that causes excessive daytime sleepiness, increasing the risk for drowsy driving two t

172 gether, our findings show that the excessive sleepiness incurred by recurrent arousals during sleep m

173 iated with atopy, fatigue, excessive daytime sleepiness, insomnia, and only 0 to 3 nights of sufficie

174 by neurologists, including excessive daytime sleepiness, insomnia, narcolepsy, rapid eye movement sle

175 Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive

176 These results indicate that sleepiness is a strong predictor of voluntary decreases

177 Daytime sleepiness is among the most common symptoms, but many p

178 Daytime sleepiness is an independent risk factor for stroke and

179 ), but its value in patients without daytime sleepiness is uncertain.

180 Subjective sleepiness (Karolinska Sleepiness Scale, KSS) and Psycho

181 It is possible that bouts of sleepiness lead to social withdrawal and loneliness, bot

182 To cope with sleepiness, many teens regularly consume highly caffeina

183 not affect rhythms of subjective hunger and sleepiness, master clock markers (plasma melatonin and c

184 Sleepiness may account for up to 20% of crashes on monot

185 SA in individuals who demonstrate subjective sleepiness may be beneficial.

186 Preliminary evidence suggests that daytime sleepiness may predate clinical diagnosis of Parkinson d

187 ference, -0.42 [0.09], P < .001) and daytime sleepiness (mean [SE] difference, -0.24 [0.09], P = .006

188 Subjective sleepiness, melatonin and cortisol were assessed hourly.

189 ondary endpoints included changes in daytime sleepiness, mood state, anxiety, and depression.

190 circadian effects were observed for reported sleepiness, mood, and reported effort; the effects on wo

191 diurnal preference, sleep quality/timing and sleepiness/mood questionnaires.

192 s with obstructive sleep apnea and excessive sleepiness; most adverse events were mild or moderate in

193 males and WDR27 in males), excessive daytime sleepiness (near AR-OPHN1) and a composite sleep trait (

194 tle change in point estimates of effect, but sleepiness no longer had a statistically significant ass

195 osterior hypothalamus completely rescued the sleepiness of these mice, but their fragmented sleep was

196 ion, consistent with decreased self-reported sleepiness on SYN115.

197 rovements in attention deficits (P < 0.001); sleepiness on the Epworth Sleepiness Scale (P < 0.001);

198 om NREM1 are a marker of severity, either of sleepiness or REM instability.

199 (P = .009, I2 = 74%), and excessive daytime sleepiness (OR, 2.27; 95% CI, 1.54-3.35) (P < .001, I2 =

200 2.65; P=0.023), those with excessive daytime sleepiness (OR, 2.51; P=0.037), and those with >/=2 medi

201 (P = .003, I2 = 76%), and excessive daytime sleepiness (OR, 2.72; 95% CI, 1.32-5.61) (P = .007, I2 =

202 that eczema associated with fatigue, daytime sleepiness, or insomnia was associated with even higher

203 rkers of arousal (including AHI), subjective sleepiness, or objective sleepiness.

204 rence, oxygen versus air, in AHI, subjective sleepiness, or objective sleepiness.

205 ot cause next-day impairment in alertness or sleepiness, or overnight hypoxaemia in OSA.

206 y and fatigue, depression, excessive daytime sleepiness, or rapid eye movement sleep behaviour disord

207 measured duration and fragmentation, daytime sleepiness, overall quality, self-reported duration) wer

208 worth Sleepiness Scale score), and objective sleepiness (Oxford Sleep Resistance Test).

209 .008); and symptoms of snoring, fatigue, and sleepiness (P < 0.001).

210 ng history, pRBD was associated with greater sleepiness (p=0.001), depression (p=0.001) and cognitive

211 CPAP improved objective sleepiness (p=0.024), mobility (p=0.029), total choleste

212 d with PD patients without excessive daytime sleepiness, patients with excessive daytime sleepiness (

213 Greater sleepiness predicted a substantial decrease in the proba

214 s not only patient-reported outcomes such as sleepiness, quality of life, and mood but also intermedi

215 tive sleepiness at 12 months, plus objective sleepiness, quality of life, mood, functionality, noctur

216 battery consisting of cognitive subtests, a sleepiness rating scale, and a mood scale, to predict ne

217 onger to fall asleep and had reduced evening sleepiness, reduced melatonin secretion, later timing of

218 d theta power but did increase self-reported sleepiness relative to controls.

219 ological fragmentation of wakefulness (i.e., sleepiness), respectively.

220 Obstructive sleep apnoea causes sleepiness, road traffic accidents, and probably systemi

221 13], P = .01) and incident OSA with habitual sleepiness (RR, 1.18 [95% CI, 1.07-1.31], P = .02).

222 associated with new-onset OSA with habitual sleepiness (RR, 2.72 [95% CI, 1.26-5.89], P = .045).

223 riority), as was the score on the Karolinska Sleepiness Scale (between-group difference, 0.12 points;

224 burgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) and objectively over 1-week using

225 intenance of Wakefulness Test (MWT), Epworth Sleepiness Scale (ESS) score >=10, and usual nightly sle

226 rimary outcome was 6-month change in Epworth Sleepiness Scale (ESS) score, which ranges from 0 (no da

227 art) were negatively associated with Epworth sleepiness scale (ESS) scores and sex (male).

228 ty, area under the curve (AUC), AHI, Epworth Sleepiness Scale (ESS) scores, blood pressure, mortality

229 he Berlin questionnaire (Bq) and the Epworth sleepiness scale (ESS) were applied to determine the ris

230 Secondary outcomes included the Epworth Sleepiness Scale (ESS), the Sleep Apnea Symptoms Questio

231 EDS was measured with the Epworth Sleepiness Scale (ESS).

232 A Persian translation of the Epworth Sleepiness Scale (ESS-IR) was used to assess of daytime

233 nd >30 indicates severe OSA) and the Epworth Sleepiness Scale (ESS; range, 0-24; >10 indicates pathol

234 icits (P < 0.001); sleepiness on the Epworth Sleepiness Scale (P < 0.001); behavior (P < 0.001); and

235 ion measured with actigraphy, the Karolinska Sleepiness Scale (with scores ranging from 1 [extremely

236 ndex [PSQI]) and daytime sleepiness (Epworth Sleepiness Scale [ESS]).

237 the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale and Morningness-Eveningness Questionnai

238 ses in subjective somnolence (via Karolinska Sleepiness Scale and Visual Analogue Scale measures) and

239 correlation between the decrease in Epworth Sleepiness Scale at 3 months and adherence (r = 0.411; P

240 ged their behavior every 30 min, completed a sleepiness scale every 3 h, and filled a sleep diary eve

241 The main outcome was the Epworth Sleepiness Scale measurement.

242 We obtained the Epworth Sleepiness Scale on 2088 community residents.

243 s with excessive daytime sleepiness (Epworth Sleepiness Scale score >/=10) had a significantly lower

244 th self-reported daytime sleepiness (Epworth Sleepiness Scale score >10) and an apnea-hypopnea index

245 >/=15/h) without daytime sleepiness (Epworth Sleepiness Scale score <10) were randomized to auto-titr

246 rovements in EDS, as assessed by the Epworth Sleepiness Scale score (mean [SD], 15.81 [3.10] at basel

247 sequent self-reported error with the Epworth Sleepiness Scale score (odds ratio [OR], 1.10 per unit i

248 utcome measure was the change in the Epworth Sleepiness Scale score comparing the bright LT with the

249 index of 20 h(-1) or greater and an Epworth Sleepiness Scale score of 10 or less (scores range from

250 th coexistent EDS, as assessed by an Epworth Sleepiness Scale score of 12 or greater, and without cog

251 of 57.1 (10.1) years and a mean (SD) Epworth Sleepiness Scale score of 9.8 (4.4), and 77.5% were post

252 The Epworth Sleepiness Scale score was reduced more with pitolisant

253 f Wakefulness Test sleep latency and Epworth Sleepiness Scale score) were met at all solriamfetol dos

254 index (AHI), subjective sleepiness (Epworth Sleepiness Scale score), and objective sleepiness (Oxfor

255 o 1.20 per one-point increase in the Epworth Sleepiness Scale score).

256 imary endpoint was the change in the Epworth Sleepiness Scale score.

257 s in the intervention group, with Karolinska sleepiness scale scores of 6.65 (95% CI, 6.35-6.97) vs 7

258 of the Northern Manhattan Study, the Epworth Sleepiness Scale was collected during the 2004 annual fo

259 ed by using a questionnaire with the Epworth Sleepiness Scale) were assessed before and immediately a

260 ality Index) and daytime sleepiness (Epworth Sleepiness Scale), and circadian markers of the melatoni

261 Of the 4608 participants who completed the sleepiness scale, 1312 (28.5%) reported excessive sleepi

262 ypopnea index, 41 [35-53]; mean [SD] Epworth sleepiness scale, 9.3 [4.2]) were randomized to effectiv

263 Composite Scale of Morningness, the Epworth Sleepiness Scale, and responded to a questionnaire about

264 luded the Epworth Sleepiness Scale, Stanford Sleepiness Scale, Functional Outcomes of Sleep Questionn

265 Subjective sleepiness (Karolinska Sleepiness Scale, KSS) and Psychomotor Vigilance Test (P

266 Secondary outcomes included the Epworth Sleepiness Scale, Stanford Sleepiness Scale, Functional

267 Secondary outcome measures were the Epworth Sleepiness Scale, the Functional Outcomes of Sleep Quest

268 to noon) by day of call cycle and Karolinska sleepiness scale.

269 ession screening instrument, and the Epworth Sleepiness Scale.

270 Coprimary endpoints were Epworth sleepiness score (ESS) at 3 months and cost-effectivenes

271 tween adherence to the DASH diet and daytime sleepiness score in adolescent girls.

272 52 yr; apnea-hypopnea index, 49/h; baseline sleepiness score, 15.7) were randomized (200 to pitolisa

273 relation between DASH-style diet and daytime sleepiness score, we applied logistic regression analysi

274 n between adherence to DASH diet and daytime sleepiness score.

275 h a specialist model did not result in worse sleepiness scores, suggesting that the 2 treatment modes

276 However, individual daytime sleepiness signals vary in their associations with objec

277 ement that described the relationships among sleepiness, sleep apnea, and driving risk.

278 We investigated the associations of sleepiness, sleep disorders, and work environment (inclu

279 aimed to investigate whether a key driver of sleepiness, sleep duration, had a similar relationship w

280 ed potential nonlinear relationships between sleepiness/sleep duration and social activity.

281 s other measures that elicited demographics, sleepiness, social support, perceptions about prior trai

282 y, poor sleep quality, and excessive daytime sleepiness, studied according to an a priori protocol.

283 In patients with OSA without daytime sleepiness, the prescription of CPAP compared with usual

284 arefully monitor changes in mood and daytime sleepiness throughout the intervention.

285 (ESS) score, which ranges from 0 (no daytime sleepiness) to 24 points (high level of daytime sleepine

286 hy might be unable, due to excessive daytime sleepiness, to accumulate the need/ability to produce re

287 Follow-up analyses showed that sleepiness uniquely moderated the effect of meditation o

288 The 42 sleepiness variants primarily cluster into two predomina

289 .2, chronotype was 63.6 +/- 10.8 and daytime sleepiness was 7.4 +/- 4.8.

290 Daytime sleepiness was also associated with NC (P = 0.02) and PP

291 tween sleepiness and motivation, the role of sleepiness was also determined.

292 The prevalence of insomnia and daytime sleepiness was not significantly higher compared with th

293 Daytime sleepiness was trichotomized using previously reported c

294 t) and OSA concomitant with habitual daytime sleepiness were estimated using repeated-measures Poisso

295 Polysomnography, cognitive performance, and sleepiness were monitored.

296 Subjective measures of sleepiness were significantly improved on clarithromycin

297 ression, along with changes in alertness and sleepiness, were assessed.

298 ted with the increased alertness and reduced sleepiness when methylphenidate was administered after s

299 moderated the typical time-of-day pattern of sleepiness, with, for example, extended evening socializ

300 /= 2 hallmarks of OSA: loud snoring, daytime sleepiness, witnessed apnea, and hypertension.